A new trading day began on Friday, with Black Diamond Therapeutics Inc (NASDAQ: BDTX) stock price up 9.32% from the previous day of trading, before settling in for the closing price of $3.11. BDTX’s price has ranged from $1.20 to $4.49 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.22%. Meanwhile, its annual earnings per share averaged 125.98%. With a float of $43.33 million, this company’s outstanding shares have now reached $56.89 million.
Black Diamond Therapeutics Inc (BDTX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Black Diamond Therapeutics Inc is 23.88%, while institutional ownership is 58.24%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares.
Black Diamond Therapeutics Inc (BDTX) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.28 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 125.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.05% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Here are Black Diamond Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.24, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Looking closely at Black Diamond Therapeutics Inc (NASDAQ: BDTX), its last 5-days average volume was 1.18 million, which is a drop from its year-to-date volume of 1.83 million. As of the previous 9 days, the stock’s Stochastic %D was 50.66%.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 97.49%, which indicates a significant increase from 90.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was higher than the 0.18 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.93, while its 200-day Moving Average is $2.31. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $3.52. Second resistance stands at $3.63. The third major resistance level sits at $3.87. If the price goes on to break the first support level at $3.17, it is likely to go to the next support level at $2.93. Now, if the price goes above the second support level, the third support stands at $2.82.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
With a market capitalization of 193.58 million, the company has a total of 56,935K Shares Outstanding. Currently, annual sales are 0 K while annual income is -69,680 K. The company’s previous quarter sales were 70,000 K while its latest quarter income was 56,540 K.
